ClinConnect ClinConnect Logo
Search / Trial NCT06443177

The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · May 29, 2024

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

A Sah Cvs Sympathetic Modulation Ruptured Brain Aneurysm

ClinConnect Summary

This clinical trial is exploring whether a procedure called spinal cord stimulation can help reduce blood vessel spasms that can occur after a brain aneurysm ruptures, known as aneurysmal subarachnoid hemorrhage. The goal is to see if adding this treatment to the usual care can improve outcomes for patients who experience these spasms, which can be serious.

To participate in the trial, individuals must be between the ages of 65 and 74, have been diagnosed with a severe type of brain bleed (Fisher grade 3 or 4), and be willing to follow the study guidelines. Participants will need to provide consent and be available for the duration of the trial. However, those who are too ill to undergo standard treatment or have certain types of aneurysms may not be eligible. If you decide to take part, you will receive the usual care for your condition along with the spinal cord stimulation procedure, with the hope of improving your recovery.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Provision of signed and dated informed consent form
  • 2. Stated willingness to comply with all study procedures and availability for the duration of the study
  • 3. Diagnosed with Fisher grade 3 or 4 aneurysmal subarachnoid hemorrhage (1)
  • 4. Ability to undergo endovascular treatment of aneurysmal subarachnoid hemorrhage
  • 5. For females of reproductive potential: Negative pregnancy test at time of treatment
  • 6. Plan to undergo standard of care and follow-up
  • Exclusion Criteria:
  • 1. Medically unfit to undergo endovascular treatment (e.g., Hunt Hess grade 5)
  • 2. Does not provide consent for the procedure.
  • 3. Posterior circulation aneurysmal subarachnoid hemorrhage.
  • 4. Initial aneurysm treatment after post bleed day 1

About University Of Alabama At Birmingham

The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.

Locations

Birmingham, Alabama, United States

Patients applied

0 patients applied

Trial Officials

Jesse Jones, MD

Principal Investigator

University of Alabama at Birmingham

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported